A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs ABBV 838 (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 05 May 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 01 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2019.